Introduction
Despite the prevalence of prostate cancer, the molecular understanding of this disease is still quite limited. In the hope of identifying new therapeutic targets, much eort is being made to characterize the genetic and molecular alterations in the upstream signaling components which may cause aberrant prostate cell growth and metastases (Huncharek and Muscat, 1995; Shi et al., 1996) . We have taken a complementary approach, of starting to de®ne the function of more downstream signaling components, the Ets transcription factors, by determining whether altering their function can speci®cally reverse features of the transformed phenotype of prostate tumor cells.
Several families of transcription factors link signal transduction pathways to gene expression. The Ets family of transcription factors act as mediators of normal and oncogenic signaling in a variety of cellular contexts (Ghysdael and Boureux, 1997; Dittmer and Nordheim, 1998) . There are over 20 unique Ets family members characterized in humans, related by their conserved DNA binding (ETS) domain (Ghysdael and Boureux, 1997) . The DNA binding speci®cities of these Ets family members are quite similar, and their functional speci®city may largely depended on their pattern of expression; interactions with partner proteins, and signal transduction pathways (Graves and Petersen, 1998) . A large variety of transformationassociated genes contain adjacent binding sites for both Ets and AP-1 family transcription factors, and such elements mediate transcriptional activation from a wide range of activated oncogenes (Wasylyk et al., 1989) . We showed that Ets binding sites alone were also sucient to confer strong Ras-responsiveness to a minimal promoter-containing reporter gene (Galang et al., 1994) , and that Ras signaling through ERK1/2 mediates speci®c phosphorylation and increased transactivation activity of Ets2 on such a reporter (Yang et al., 1996; McCarthy et al., 1997) . Many other Ets transcription factors have also been found to be targets of Ras pathway signaling (reviewed in Ghysdael and Boureux, 1997; Wasylyk et al., 1998) .
Ets factors are not only downstream targets of oncogene signaling, but they also play an important role in mediating the transformed phenotype. Analysis with dominant inhibitory Ets2 constructs indicates that Ets factors are required for the initiation of murine ®broblast transformation by oncogenic Ras or Neu (Langer et al., 1992; Galang et al., 1996) . In addition, stable expression of the DNA binding domain (the ETS domain) from several divergent Ets family members was found to reverse the transformed phenotype of stably Ras-transformed NIH3T3 cells, but not to inhibit attached cell growth (Wasylyk et al., 1994) . Surprisingly, expression of full-length Ets2 (an activator of Ets-dependent transcription), or an even more powerful activator (VP16-Ets2) in Ras transformed NIH3T3 cells reversed their transformed phenotype more eciently than expression of just the Ets2 DNA binding domain (Foos et al., 1998) . While these approaches using dominant acting Ets constructs do not reveal which particular Ets factors may be involved in transformation, they are of value in establishing the importance of this large family of transcription factors in this process.
Ets factors also play a role in the transformed phenotype of spontaneously arising human tumor cells. Expression of the Ets2 DNA binding domain (Ets2DBD) inhibited anchorage-independent growth and invasiveness of the BT-20 breast tumor cell line (Sapi et al., 1998) . Expression of full-length Ets1 was also found to reverse the transformed phenotype of the human DLD-1 colon tumor cell line, and this reversion activity was lost in an Ets1 point mutant that had lost transactivation activity (Suzuki et al., 1995) . Altered Ets activity has been reported to sensitize tumor cells to apoptotic death. Expression of an Ets1 splice variant induced apoptosis in serum starved DLD-1 colon tumor cells , PU.1 expression sensitized erythroleukemia (MEL) cells to DMSOinduced apoptosis (Yamada et al., 1997) , and expression of Elk1 sensitized MCF-7 breast tumor cells to apoptosis upon calcium ionophore treatment (Shao et al., 1998) .
The direct mutational activation of Ras in prostate tumors appears to be quite infrequent (Konishi et al., 1997) , and activating ras mutations are not present in the commonly used prostate tumor cell lines such as PC-3, DU145, or LNCaP (Gumerlock et al., 1991) . However, a variety of other upstream signaling components converge on Ets factors. Ets2 expression is elevated in several prostate tumor specimens (Liu et al., 1997) , and Ets factors activate the expression of the maspin tumor suppressor in normal prostate epithelial cells (Zhang et al., 1997) . Androgen receptor interaction with Ets proteins is reported to downregulate expression of matrix metalloproteinases in prostate tumor cells (Schneikert et al., 1996) . In a preliminary analysis of the role of Ets factors in prostate tumor cell lines, expression of either an Ets2 antisense construct or the Ets2 DBD reduced the size of soft agar colonies formed by PC3 or DU145 cells (Sementchenko et al., 1998) . Much of what has thus far been learned about the molecular biology of prostate cancer has come from the analysis of established prostate tumor cell lines (Royai et al., 1996; Webber et al., 1997) . We have utilized the hormone-independent metastatic human prostate tumor cell line PPC-1, stably expressing two distinct dominant acting Ets2 constructs, as an initial model system to broadly assess the function of Ets factors in multiple criteria of transformation. We demonstrate here, that in addition to the previously reported eects on colony size (Sementchenko et al., 1998) , that Ets-dependent gene expression aects many of the transformed features of this prostate tumor cell line, including anchorage-independence, apoptosis, motility, and invasiveness.
Results

Generation of PPC-1 prostate tumor cell lines stably expressing Ets2 constructs
To test whether Ets factor activity is important for the transformed phenotype of a human prostate tumor cell line, we generated PPC-1 cell lines expressing Ets2 constructs designed to either inhibit or activate Ets-dependent transcription. The PPC-1 cell line was originally described as derived from a primary prostatic carcinoma (Brothman et al., 1989) .
However, subsequent karyotypic analysis (Chen, 1993) has led to the conclusion that PPC-1 cells are actually a diverged clonal variant of the prostate tumor metastasis-derived PC-3 cell line (www.ATCC.org), and their similar phenotypes support this idea. PPC-1 cells exhibit a highly transformed phenotype, including androgen independent and anchorage-independent growth. PPC-1 cells are invasive in in vitro assays (Wasilenko et al., 1996) , and are both tumorigenic and metastatic in nude mice (Brothman et al., 1989 (Brothman et al., , 1991 . PPC-1 cells were transfected with expression constructs for either the Ets2 DNA binding domain, for full-length Ets2, or the empty expression vector, pCIN4. Multiple independent stable clones were generated with each construct. In the pCIN4 vector, G418 resistance is conferred by the 3' gene in a bicistronic message. Therefore, the G418-resistant clones that were selected should all express the 5' Ets2 construct. There were approximately 10-fold fewer stable colonies generated with the full-length Ets2 expression construct relative to the other two plasmids, indicating possible toxicity of Ets2 overexpression in PPC-1 cells (see below). Initial analysis revealed that six of eight randomly selected clones generated with the Ets2DBD and seven of 12 generated with full-length Ets2 expressed easily detectable amounts of these constructs.
Expression of either full-length Ets2 or the Ets2DBD alone specifically inhibits anchorage-independent PPC-1 cell growth
To determine whether expression of full-length Ets2 or the Ets2 DNA binding domain alone could speci®cally inhibit the ability of PPC-1 cells to grow in an anchorage-independent manner, we compared the ability of the various cell lines to grow in soft agar relative to their ability to grow attached in normal tissue culture dishes. Preliminary analysis revealed that virtually all of the Ets2DBD or full-length Ets2-expressing clones exhibited signi®cantly impaired growth in soft agar, whereas none of six pCIN4 vector only-containing clones assayed showed this reduction in anchorage-independent growth. Subsequently, two pCIN4 clones, two Ets2DBD expressing clones, and three full-length Ets2-expressing clones were then chosen as representative cell lines for the detailed analysis described below. Figure 1a shows that PPC-1 cell clones expressing either the Ets2DBD or full-length Ets2 showed a strong inhibition of soft agar growth relative to the parental PPC-1 cells or lines containing empty pCIN4 expression vector, with some Ets2full and Ets2DBD expressing clones exhibiting more than a 10-fold reduction in soft agar colony formation. Parallel plating experiments on tissue culture dishes, using the same dilution of cells used in the soft agar assay, showed that the Ets2 construct-expressing clones could form the same number of colonies as control cell lines (data not shown).
Expression of the introduced Ets2 constructs in the PPC-1 cell lines was measured by immunoblotting of whole cell extract with an antibody directed against the FLAG epitope tag on the Ets2 and Ets2DBD constructs. A range of full-length Ets2 expression was seen in the dierent clones derived with the Ets2full expression construct (Figure 1b) , with E2full#11 and E2full#52 showing high Ets2 expression, and E2full#1 expressing moderate amounts of Ets2. The amount of Ets2 expression in these lines (Figure 1b) corresponded to the degree of soft agar growth inhibition, as shown in Figure 1a . Similarly, a range of Ets2DBD expression was seen in the individual stable PPC-1 cell lines derived with Ets2DBD expression construct, and a clone expressing a high amount of Ets2DBD (Ets2DBD#5) showed the greatest inhibition of soft agar growth (Figure 1a and data not shown). Because of the selective pressure against high Ets2 construct expression (see below), there was some variation over time in the absolute amount of Ets2 construct expressed in the stable cell lines. However, the generally high or low Ets2 construct expression was stably maintained in these PPC-1 cell clones throughout passaging required to complete the various biological assays (data not shown).
The amount of introduced full-length Ets2 relative to the endogenous Ets2 in PPC-1 cells was estimated by immunoblotting using an Ets2-speci®c antibody. Quantitative analysis of the signals shown in Figure 1c revealed that the Ets2full#11 and Ets2full#1 clones were expressing about eight-and ®vefold more Ets2 than the parental cells, respectively. Thus, these stable PPC-1 cell clones are signi®cantly overexpressing Ets2, and the eightfold overexpressing Ets2full#11 line exhibits strong inhibition of both attached and soft agar cell growth. Extract from PPC-1 cells transiently transfected with the Ets2 expression construct ( Figure  1c , lane 2) was used to con®rm the identity of the Ets2 band, and use of a distinct Ets2-speci®c antibody that we generated (McCarthy et al., 1997) gave similar quantitative results (data not shown). Overall, expression of either full-length Ets2 or just the DNA binding domain of Ets2 speci®cally inhibited the anchorageindependent growth of PPC-1 cells.
Expression of Ets2 or the Ets2DBD increases the attached cell doubling time
We previously found that expression of full-length Ets2 or the Ets2DBD strongly inhibited the anchorageindependent growth of a Ras-transformed NIH3T3 cell line, but did not inhibit its attached cell growth (Foos et al., 1998) . In contrast, we observed that the Ets2 construct-expressing PPC-1 clones formed smaller attached cell colonies and grew more slowly than the PPC-1 cell lines containing the empty pCIN4 expression vector. Analysis of the attached cell growth rate of the PPC-1 clones (Figure 1b ) revealed that the clones expressing high levels of either Ets2 or the Ets2DBD showed a large increase in doubling time. While the parental PPC-1 cells had a doubling time of 28 h, the lines expressing high levels of full-length Ets2 (#11 and #52) had doubling times of 42 and 59 h respectively. Similarly, the line expressing the most Ets2DBD (#5) had a 50 h doubling time. The slower growth rate of Ets2 or Ets2DBD-expressing cells raised the question whether the failure to form visible soft agar colonies by these clones was simply due to these cells taking longer to form colonies. Examination of soft agar colonies stained with the vital dye INT showed that after 3 weeks of growth, PPC-1 colonies consisted of hundreds of metabolically active cells, whereas the colonies from the Ets2-expressing PPC-1 cell lines consisted of only a few metabolically inactive cells (data not shown). Clearly this dierence in the soft agar growth was not simply due to a twofold reduction in the attached cell growth rate.
Increased apoptotic cell death in PPC-1 cells expressing Ets2 constructs
We observed in the routine culturing of stable PPC-1 clones expressing either the Ets2DBD or full-length Ets2, that in addition to a slower apparent growth rate (Figure 1b) , there was a signi®cantly larger number of dead and dying cells present. This cell death was not observed in cultures of the parental PPC-1 cells or in clones generated with the empty pCIN4 vector. Morphological examination of cells stained with acridine orange and ethidium bromide revealed that multiple clones expressing either the Ets2DBD or fulllength Ets2 showed up to a ninefold increase in the number of cells exhibiting membrane blebbing or nuclear condensation, relative to the parental cell line PPC-1 or pCIN empty vector clones (data not shown). Such morphological changes suggested a signi®cant portion of the Ets2 construct-expressing cells were apoptotic.
As an independent assay for apoptotic death, we analysed whether these cells exhibited membrane inversion, an early event in apoptosis. The cells were stained with¯uorescene-conjugated annexin-V and propidium iodide, and then analysed by FACS. The results of a representative experiment are shown in Figure 2 . In both the parental cell line PPC-1 and the empty vector control line pCIN#56, very low levels of Annexin-V positive and propidium iodide negative (apoptotic) cells were present (1.9 and 0.9% respectively). However, in PPC-1 cells expressing a high amount of Ets2, Ets2full#52, 16.5% of the cells were scored as apoptotic. Similarly, Ets2DBD expressing cell lines also exhibited increased apoptosis, with 11.5% of the cells scored as apoptotic in Ets2DBD#5, the high Ets2DBD expressing line. The level of apoptosis in these asynchronously dying cells was likely even higher than was scored in Figure 2 , as to exclude possibly necrotic cells, the Annexin V positive cells that were also propidium iodide stained were not counted. Multiple independent experiments yielded similar results, with an increase in apoptotic cells for the Ets2 full lines and the Ets2DBD lines with high levels of Ets2 construct expression. Thus, stable overexpression of either the Ets2DBD or full-length Ets2 leads to a dramatic increase in apoptosis in PPC-1 cells.
Expression of the Ets2DBD has opposite effects on Ets-dependent reporter genes in PPC-1 cells and MDA-MB-435 cells
To determine whether Ets2DBD also acts as a dominant inhibitor of Ets dependent transcription in PPC-1 cells, we compared the eects of this construct on Ets dependent reporter constructs in PPC-1 cells and the MDA-MB-435 breast tumor cell line ( Figure  3a) . Empty expression vector, or an expression construct for full-length Ets2 (pCINE2full), or for the Ets2DBD (pCINEts2DBD) was cotransfected with either the minimal promoter-containing D56-Fos-Luc reporter, this reporter with multiple palindromic Ets2 binding sites (E.36) which is preferentially activated by Ets2, or with multiple Ets-AP-1 elements (Py2), which is activated by several Ets factors including Ets2. As expected, increased expression of full-length Ets2 activated the expression of the Ets-dependent E.36-luc reporter gene in both cell lines (Figure 3a) . Unexpectedly, expression of the Ets2DBD in PPC-1 cells activated E.36-luc reporter gene expression eightfold and Py2-luc fourfold. In contrast, and similar to our previous observations in NIH3T3 cells (Galang et al., 1996) , the Ets2DBD inhibited expression of the E.36-luc and Py2-luc reporters in MDA-MB-435 cells (Figure 3a) .
Ets-dependent gene expression is elevated in PPC-1 cells stably expressing Ets2 or Ets2DBD
To determine whether similar alterations in Etsdependent gene expression occur in the PPC-1 clones stably expressing the various Ets2 constructs, we used these stable cell lines for additional reporter gene analysis. Each stable clone was transfected with the D56Fos reporter, or the Ets-dependent reporter genes E.36 or Py2. Figure 3b shows the expression of E.36 or Py2 relative to the expression of D56Fos in the same line. Similar to the unexpected results obtained in the transient cotransfection studies above, there was increased expression of the E.36 and Py2 reporter genes in the EtsDBD overexpressing PPC-1 line. The expression of Py2 relative to D56Fos (22-fold) in this line was higher than the control cell line (12-fold) or for the full-length Ets2 expressing lines tested (8-and 11-fold).
PPC-1 cells expressing Ets2 or Ets2DBD have increased levels of p21 Cip
The altered growth properties and increased apoptosis observed in Ets2 construct-expressing PPC-1 cells suggests that the cyclin-dependent kinase inhibitors could be a potential downstream target. Expression of p21
Cip is activated by hyperstimulation of the Ras/Raf signaling pathway (Woods et al., 1997) , and p21
Cip has been reported to be a direct transcriptional target of overexpressed Ets factor E1AF (Funaoka et al., 1997) . We measured the steady-state levels of p21
Cip and the related p27
Kip1 protein in the stable cell lines using immunoblot analysis (Figure 4) . Relative to the low levels of p21
Cip protein in the parental PPC-1 cell line or the pCIN empty vector lines, p21
Cip protein expression was signi®cantly elevated in multiple PPC-1 cell lines that express either full-length Ets2 or Ets2DBD (Figure 4a) . The highest amount of p21 protein in the Ets2full lines was observed in Ets2full#52, a high expresser of Ets2, whereas the lowest p21 induction was in Ets2full#51 (Figure 4a ), a clone with little Ets2 expression (data not shown). Interestingly, elevated p21
Cip levels were also observed in PPC-1 lines reverted by expression of the dominant inhibitory Ets2DBD construct (Figure 4a and data not shown). The elevation of p21
Cip levels by expression of either full-length Ets2 or Ets2DBD may be a result of direct transcriptional regulation of p21
Cip by Ets factors, as in PPC-1 cells, both of these Ets2 constructs can cause activation of Ets-dependent transcription.
To measure the amount of p21 Cip and p27 Kip1 mRNA in the reverted cells, we performed RNase protection experiments (Figure 4b ). The levels of p21 and p27 expression were normalized to the expression of the internal cyclophilin control for each sample. Nearly identical results were obtained normalizing to a GAPDH internal control (data not shown). Quantitative analysis revealed that p27
Kip1 mRNA levels were not signi®cantly altered compared to both negative control lines, but p21
Cip expression was elevated in the lines expressing the most full-length Ets2 or EtsDBD, with the maximum observed stimulation of 2.4-fold in the Ets2full#11 line (see Figure 4b ). To determine whether the elevated p21 expression could be a transcriptional consequence of altered Ets activity in PPC-1 cells, we tested the ability of reporter genes containing portions of the p21 Cip promoter to be transactivated by cotransfection of Ets2 or the Ets2DBD in these cells (Figure 4c ). The p21
Cip reporter 0-luc was maximally activated 7.6-fold by full-length Ets2, similar to the 8.4-fold Ets2 activation of the truncated 4-luc p21 reporter. Dose-response analysis indicated that this amount of Ets2 expression construct also gave maximal expression of the synthetic Ets2-responsive reporter E.36-luc (data not shown). While expression of the Ets2 DBD did not exhibit signi®cant eects with this reporter, the stimulation of p21
Cip expression by full-length Ets2 in this cotransfection assay was signi®cantly larger than that seen with the D56fos-luc control reporter (Figure 4c) . Overall, the eects of Ets2 on both the endogenous p21 and the p21 reporter genes suggests that p21 may be a direct target of Ets signaling in the reverted PPC-1 cells.
Decreased motility in cell lines expressing Ets2 constructs We examined motility of the PPC-1-derived cell lines through an 8 mm pore uncoated ®lter in response to a serum gradient. As shown in Figure 5a , or Py2 (striped bars) reporters, and with either empty pCIN4 expression vector or expression constructs for Ets2DBD or fulllength Ets2 (E2full). The fold activation is the luciferase activity of each reporter contransfected with E2DBD or E2full, relative to luciferase activity from that reporter in the same cell line cotransfected with pCIN4. (b) Relative expression of reporter genes transfected into PPC-1 cell lines stably expressing Ets2 constructs. The expression of the E.36 or Py2 reporters relative to the expression of D56fos in each indicated cell line is shown. Assays were done in parallel experiments, and the average and standard error of the assays is shown PPC-1 cells expressing either Ets2full or Ets2DBD showed signi®cantly reduced motility in this assay, exhibiting 17 to 37% of the motility of the parental cell line PPC-1. A control cell line, pCIN#56, which contains only the empty expression vector, did not show signi®cantly altered motility. An average of 600 PPC-1 cells migrated through the membrane in 16 h, using the conditions described in Materials and methods. The reduction in motility was proportional to the level of the expression of either of the dierent Ets2 constructs (see Figure 1b) . The strong reduction in apparent motility was not simply a consequence of reduced cell division, because the measurements took place over less than one doubling time. Overall, stable expression of either full-length Ets2 or the Ets2DBD inhibited PPC-1 cell motility.
Overexpression of Ets2DBD but not full-length Ets2 in PPC-1 cells blocks in vitro invasion Invasion through basement membranes is an important step in the metastatic process. We have assayed the in vitro invasion potential of PPC-1 cells expressing full-length Ets2 or Ets2DBD, by measuring their ability to traverse through ®lters coated with reconstituted basement membrane (Matrigel). NIH3T3 cell conditioned RPMI media was used as a chemoattractant. Figure 5b shows that the cell lines expressing the Ets2DBD exhibited signi®cantly reduced invasiveness in these assays. For the Ets2DBD#5 line, the percentage of invading cells was comparable to that of the normal NIH3T3 cells (Figure 5b) . Interestingly, despite the parallel changes in phenotype of full-length Ets2 expressing PPC-1 cells with the Ets2DBD lines in the other assays described above, the cell lines expressing full-length Ets2 showed no reduction in their invasion activity. If anything, PPC-1 cells expressing full-length Ets2 were slightly more invasive than the parental PPC-1 cells (Figure 5b ). These results suggest that full-length Ets2 and the Ets2DBD, have some distinct targets in PPC-1 tumor cells.
Discussion
In this study, we have utilized prostate tumor cell line clones stably expressing dominant acting Ets2 constructs to demonstrate that Ets factors can mediate diverse aspects of the transformed phenotype. Altering Ets-dependent gene expression in two distinct ways, by either stably expressing an activator (full-length Ets2) or a dominant inhibitor (the Ets2DBD) greatly inhibited anchorage-independent PPC-1 cell growth. These results were similar to what we previously observed with Ras transformed murine ®broblasts Kip1 protein levels. Equal amounts of protein from whole cell extracts were immunoblotted and probed with a combination of antibodies against p21 CIP/WAF and p27
Kip1
. The speci®c signals for p21 and p27 are indicated. (b) Multiplex RNase protection assay where RNA samples from each indicated cell line were simultaneously analysed with probes from p27, p21, and cyclophilin. The indicated bands were quantitated and normalized to the cyclophilin internal control. The relative expression shown below the lanes are the ratio of the normalized signal to the corresponding signal from the empty vector-containing pCIN#6 cell line. (c) Transient cotransfection assay of a p21 reporter gene with Ets2 constructs in PPC-1 cells. The cells were cotransfected with the p21 reporters 0-luc or 4-luc, or the D56fos-luc reporter, and either empty expression vector (pCIN4), or Ets2full or Ets2DBD expression constructs. The fold activation is the ratio of luciferase activity of the reporter when cotransfected with Ets2full (white bars) or Ets2DBD (black bars) relative to the same reporter cotransfected with pCIN4 (Foos et al., 1998) , and we have also observed that the Ets2DBD DNA binding activity is required for reversion activity (C Galang and CA Hauser, unpublished observations). However, in contrast to reverted NIH3T3 cells, high expression of either fulllength Ets2 or the Ets2DBD in PPC-1 cells caused an apparent reduction in the attached cell growth rate. This was due, at least in part, to the fairly dramatic induction of apoptosis. While expression of the Ets2DBD or full-length Ets2 had several common eects on PPC-1 cells, a striking dierence was observed in the invasive behavior of the cell lines expressing these distinct Ets2 constructs. PPC-1 cells expressing the Ets2DBD almost completely lost their in vitro invasion activity, whereas cell lines expressing full-length Ets2 were fully invasive. Thus, these two types of Ets2 constructs are not acting through identical mechanisms. The observed eects of altered Ets activity on tumor cell growth, survival, and invasiveness, were veri®ed in multiple independent clonal cell lines for each construct, and the eects correlate with the levels of Ets2 construct expression.
Altering the balance of Ets-dependent gene expression had a strong eect on PPC-1 cell survival, as there was up to a 10-fold increase in the number of apoptotic cells observed in Ets2 construct-expressing PPC-1 clones (Figure 2 ). This somewhat unusual steady-state apoptosis is likely the consequence of selecting for stable PPC-1 clones expressing enough of the Ets2/ NPT bicistronic message to confer G418 resistance, but not so much Ets2 as to cause an amount of cell death which overrides the cell growth. Because G418 does not induce apoptotic death (Chen et al., 1995) , the observed apoptosis is not simply from insucient G418 resistance. The mechanism by which apoptotic pathways are regulated by Ets factors are not clear. In the case of the p42 Ets1 splice variant, expression of this truncated protein, but not full-length Ets1, sensitized DLD-1 colon tumor cells to Fas-mediated apoptosis, and this cell death required caspase-1 activation (Li et al., 1999) . In contrast, expression of full-length Ets2 was reported to inhibit apoptosis in macrophages upon growth factor withdrawal, and was postulated to act through transcriptional induction of bcl-x(L) (Sevilla et al., 1999) . In Drosophila, a genetic study found that loss-of-function allele of the pointed P2 Ets factor sensitized eye cells to apoptosis upon hid overexpression (Kurada and White, 1998) . Unlike these previous reports, where altered Ets factor activity sensitized cells to apoptosis-inducing agents, apoptosis occurred spontaneously in the Ets2 construct-expressing PPC-1 cells described here. Thus, Ets signaling can have a strong direct eect on the survival of this prostate tumor cell line.
We initially postulated that full-length Ets2 acts as an activator of Ets-dependent transcription, and the Ets2DBD would bind non-productively to Ets binding sites to broadly inhibit Ets-dependent gene expression in PPC-1 cells. This was the result we observed in NIH3T3 cells (Galang et al., 1996; Foos et al., 1998) . However, with the exception of invasiveness, there was extensive similarity in the altered phenotype of PPC-1 clones expressing either the presumptive activator or inhibitor of Ets-dependent transcription. When we directly tested the transcriptional eects of full-length Ets2 and the Ets2DBD in PPC-1 cells using transient cotransfection assays, we found that while full-length Ets2 does indeed activate expression of the Etsdependent reporters, the Ets2DBD also unexpectedly activated reporter gene expression (Figure 3a) . This transactivation by the Ets2DBD was not only in contrast to the results in NIH3T3 cells, but also the opposite result of that seen in the MDA-MB-435 breast tumor cells analysed in parallel with the PPC-1 cells (Figure 3a) . Analysis of PPC-1 clones stably expressing either Ets2 or the Ets2DBD also showed that expression of the Ets2DBD increased the expression of Ets-dependent reporters (Figure 3b) . Finally, a similar activation by the Ets2DBD was seen in the analysis of a potential Ets target gene p21 In vitro invasion assays of the indicated stable PPC-1 clones were performed using invasion chambers coated with Matrigel, as described in Materials and methods. The invasion rate of pCIN#56 (which averaged 355 cells/®eld) was de®ned as 100%. The relative invasion rate of each indicated clone is shown, and represents the average of triplicates from three dierent experiments (Figure 4b,c) . This induction of p21 cip expression by either Ets2 construct may be partially responsible for the reduced growth rate of PPC-1 cells expressing these constructs (Figure 1b) . We have not yet identi®ed essential Ets binding sites in the p21 promoter, but neither of the two previously characterized upstream overlapping Ets/p53 binding sites at approximately 72.2 kb and 71.3 k (Funaoka et al., 1997; Beier et al., 1999) are present in the 4-Luc reporter. In addition, PPC-1 cells are reported to contain only mutant p53 (Borner et al., 1995) , so interaction with p53 is an unlikely mechanism for the Ets2 constructs in regulating p21 expression in these cells. Possible mechanisms for transactivation by the Ets2 DNA binding domain alone, more pronounced in the synthetic E.36 and Py2 reporters, is that it acts by displacing Ets family transcriptional repressors (e.g. ERF, TEL, or NET), or that it binds DNA and recruits other activator proteins through protein ± protein interactions. We are now investigating whether, unlike other cell types, PPC-1 cells or other prostate tumor cell lines have a functional predominance of Ets family repressor proteins.
The ability of prostate tumor cells to invade through basement membrane is a key component of their metastatic behavior. It is likely that Ets factors in¯uence the expression of many metalloproteinases (MMPs) associated with invasiveness, as Ets binding sites are regulatory elements in the promoters of many of these MMP genes (reviewed in Crawford and Matrisian, 1996; Borden and Heller, 1997) . Altered Ets activity has been reported to impair the motility or invasiveness of other cell types. Ets1 antisense oligonucleotides inhibited the motility and invasiveness of endothelial cells , and expression of the Ets1DBD or Ets2DBD inhibited the migration and invasiveness of breast tumor cell lines (Sapi et al., 1998; Delannoy-Courdent et al., 1998) . We show here that stable expression of the Ets2DBD resulted in a complete inhibition of the in vitro invasiveness of PPC-1 cells. This result was in sharp contrast to expression of full-length Ets2 in PPC-1 cells, which exhibited no inhibition of in vitro invasiveness ( Figure 5 ). These results indicate that full-length Ets2 and the Ets2DBD do have some distinct biologically important targets in PPC-1 cells. We do not yet know the mechanism by which Ets2 or the Ets2DBD are dierentially regulating target gene expression, but it may depend on promoter context. We are now undertaking several approaches to determine which of the many genes associated with invasiveness (e.g. MMPs, TIMPs, and integrins) exhibit altered expression in the various PPC-1 cell clones.
In summary, we have found that Ets factor activity can strongly in¯uence the transformed and invasive phenotype of a human prostate tumor cell line. This novel linkage of Ets signaling to features such as the survival and invasiveness of a prostate tumor cell line, suggests that Ets proteins and the signaling pathways that control their activity may represent potentially useful targets for the treatment of prostate cancer. It will be of great interest to characterize the Ets target genes and the mechanisms by which they regulate the transformed phenotype of PPC-1 cells, and to determine the generality of these pathways in other prostate tumor cells.
Materials and methods
Cell growth and selection
The PPC-1 human prostatic carcinoma cell line was originally obtained from ATCC, and was cultured in RPMI 1640 media supplemented with 10% fetal calf serum (Gemini). The PPC-1 cells were transfected by the calcium phosphate method we previously described (Foos et al., 1998) , except that for a 10 cm dish, 10 mg of pCINderived expression plasmid DNA and 10 mg of high molecular weight herring testes carrier DNA were used. Stable colonies were selected 3 days after transfection using media containing 400 mg/ml of active G418 (Calbiochem). Multiple isolated PPC-1 cell clones derived from each expression plasmid were randomly picked, expanded and passaged in the presence of 400 mg/ml G418 for subsequent analysis.
Ets2 expression plasmids
We have previously described the expression constructs for the FLAG epitope tagged Ets2 DNA binding domain (Ets2DBD) and the full-length Ets2 (Ets2full) in the pCIN4 vector (Foos et al., 1998) . The CMV-driven pCIN4 expression vector is a derivative of the pCIN plasmid (Rees et al., 1996) , and the Ets2 expression constructs in this vector express a bicistronic message encoding the inserted Ets2 coding sequences at the 5' end, an IRES, and then the NPT gene encoding G418 resistance.
Attached colony and soft agar growth assays
Soft agar assays were essentially performed as previously described (Clark et al., 1995) with 1000 cells plated in soft agar without G418. The soft agar plates were fed with 0.5 ml growth media every 3 days, and after 14 days, the cells were stained 14 h with the vital dye p-Iodonitrotetrazolium violet (INT). Soft agar colonies visible without magni®cation were counted manually. In parallel to each soft agar assay, an attached growth assay was performed, where 400 cells from the same cell dilutions were plated in 50% standard growth media and 50% conditioned growth media on standard tissue culture dishes and grown for 7 days. Conditioned media was standard growth media in which *30% con¯uent attached PPC-1 cells were grown for 24 h, which was then collected and sterile ®ltered. Attached colonies were stained with crystal violet and counted. The number of soft agar colonies for each cell line was then normalized by multiplying by the ratio (attached colonies from PPC-1 cells)/(attached colonies from the cell line) in the same experiment. The doubling times for the cell lines were determined by plating 2000 cells in quadruplicate plates, and then harvesting dishes after 24, 48, 72, or 96 h and counting the cells in a hemocytometer.
Immunoblotting
Immunoblots were performed using whole cell extracts containing equal amounts of total protein. The FLAG epitope tagged Ets2 proteins were detected in immunoblots using the anti-FLAG M5 monoclonal antibody (Kodak). Analysis of the ratio of endogenous Ets2 to introduced Ets2 was performed by immunoblotting with the Ets2(C-20) antibody (Santa Cruz Biotechnology). Immunoblot signals were quantitated by imaging luminescence with Pierce Supersignal substrate, using a ChemiImager (Alpha Innotech). The p21/p27 proteins were detected using anti-CIP/ WAF and anti-Kip1/p27 (Transduction Laboratory) after immunoblotting extracts made from subcon¯uent cells. Both the anti-p21 and p27 antibodies gave the expected speci®c signals when used alone.
Apoptosis assays
For analysis of nuclear and cytoplasmic morphology, attached cells were washed with PBS, then stained with 4 mg/ml each of acridine orange and Ethidium Bromide in PBS. For the analysis of membrane inversion, the ANNEX-IN-V-FLOUS kit (Boehringer-Mannheim) was used as recommended by the manufacturer. In brief, cells¯oating in the media and those removed from the dish with trypsin/ EDTA were collected by centrifugation. The cells were resuspended in PBS, and then stained with propidium iodide and¯uorescein conjugated Annexin V, and analysed by FACS (Becton Dickinson).
Reporter gene and RNase protection assays
We have previously described the minimal promoter-containing reporter plasmid D56fos-luc, and its Ets-responsive derivatives, E.36-luc and Py2-luc (Foos et al., 1998) . The p21 cip reporters 0-luc and 4-luc contain the p21 cip promoter sequences from 72326 to +16 or 7883 to +16 respectively, fused to the luciferase coding sequence (Zeng et al., 1997) , and were generously provided by Dr WS El-Diery. Transfections for reporter gene assays were performed using Lipofectamine Plus (Gibco BRL) as recommended. In brief, 12-well dishes of 50% con¯uent cells were transfected using 0.03 mg of reporter plasmid and 0.45 mg of pCIN4-derived Ets2 expression constructs or the empty pCIN4 vector for each well. For each transfection, 5 ml PLUS reagent and 2.5 ml Lipofectamine were used. Sixteen hours following transfection, the growth media was replaced with media containing 0.5% calf serum, and the cells were incubated for an additional 6 h before harvest. Luciferase activity was quantitated using the Promega Luciferase Assay System and a Berthold Microlumat LB 96P luminometer. Transfection eciency and non-speci®c eects were controlled as we previously described (Hauser et al., 1995) , by analysing multiple replicates, and the standard deviations are shown.
RNase protection assays were performed using the RPA II kit from Ambion as recommended by the manufacturer, and the results quantitated by phosphorimager. Templates to generate control probes for human cyclophilin and GAPDH were also obtained from Ambion. Templates for human p21 and p27 RNase protection probes were generated by RT ± PCR ampli®cation of bases 150 ± 345 and 34 ± 269 of the p21 and p27 coding sequences respectively, which were then cloned into the pcDNA3 vector.
Invasion and motility assay
Biocoat Matrigel invasion chambers (Becton Dickinson Labware) were used to assess the invasiveness of the stable PPC-1 clones. Matrigel inserts (24-well format) were placed in wells containing 0.375 ml of standard growth media (RPMI+10% FCS) and 0.375 ml of the same media conditioned by NIH3T3 cells. Then 4610 4 cells in 0.5 ml serum free RPMI media were added to the chambers and the plates were incubated for 24 ± 36 h at 378C, 5% CO 2 . Cells remaining on the upper ®lter surface were removed by scrubbing with cotton tipped swabs. The ®lter inserts were stained with crystal violet and all of the cells on the bottom of the ®lter were counted under 1006magni®cation. The relative invasion was calculated relative to the average invasion of the control pCIN#56 cells in the same triplicate experiment. The standard deviation was the variation of the relative means between three separate experiments. Motility assays were performed using Biocoat Control inserts, which contain uncoated eight micron pore ®lters. Motility assays were performed, quantitated, and analysed similar to the invasion assays, except that RPMI containing 10% fetal calf serum was used as the chemoattractant, and the cells stained after 16 h.
